Inhibition of DNA methylation during chronic obstructive bladder disease (COBD) improves function, pathology and...

Area of Science:

• Urology
• Epigenetics
• Molecular Biology

Background:

• Chronic obstructive bladder disease (COBD) arises from persistent bladder dysfunction after obstruction relief.
• Epigenetic alterations, specifically DNA methylation, are implicated in the chronic nature of COBD.
• Understanding these epigenetic changes is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the effects of the hypomethylating agent decitabine (DAC) on COBD.
• To determine if inhibiting DNA methylation can reverse or alleviate COBD pathophysiology.
• To explore the role of DNA methyltransferase (DNMT) 3A in bladder smooth muscle cell function.

Main Methods:

• COBD was induced in female Sprague-Dawley rats via urethral ligation for 6 weeks, followed by suture removal.
• Animals received either DAC treatment or vehicle (normal saline) post-obstruction removal.
• Bladder function, residual volume, bladder mass, gene expression (qPCR), and protein levels (immunostaining) were assessed.

Main Results:

• DAC treatment significantly improved voiding efficiency in COBD rats compared to vehicle-treated controls.
• Brain-derived neurotrophic factor (BDNF) variants 1 and 5 were upregulated by COBD and reduced by DAC.
• DAC reduced collagen deposition but did not resolve bladder hypertrophy; DNMT3A overexpression impaired smooth muscle cell function.

Conclusions:

• Inhibition of DNA methylation with DAC post-obstruction enhances functional recovery in COBD.
• DAC treatment appears to modulate BDNF expression, contributing to improved bladder function.
• Targeting DNA methylation pathways offers a potential therapeutic strategy for chronic obstructive bladder disease.